Lack of resistance of Plasmodium falciparum to dihydroartemisinin in Uganda based on parasitogolgical and molecular assays by Cooper, Roland A. et al.
Dominican Scholar
Collected Faculty and Staff Scholarship Faculty and Staff Scholarship
2015
Lack of resistance of Plasmodium
falciparum to dihydroartemisinin in
Uganda based on parasitogolgical and
molecular assays
Roland A. Cooper
Department of Natural Sciences and Mathematics, Dominican University of California,
roland.cooper@dominican.edu
Melissa D. Conrad
Department of Medicine, University of California, San Francisco
Quentin D. Watson
Department of Integrative Biology, University of California, Berkeley
Stephanie J. Huezo
Department of Integrative Biology, University of California, Berkeley, shuezo906@gmail.com
Harriet Ninsiima
Infectious Diseases Research Collaboration, Kampala, Uganda
See next page for additional authors
Survey: Let us know how this paper benefits you.
This Conference Proceeding is brought to you for free and open access by the Faculty and Staff Scholarship at Dominican
Scholar. It has been accepted for inclusion in Collected Faculty and Staff Scholarship by an authorized administrator of
Dominican Scholar. For more information, please contact michael.pujals@dominican.edu.
Recommended Citation
Cooper, Roland A.; Conrad, Melissa D.; Watson, Quentin D.; Huezo, Stephanie J.; Ninsiima, Harriet;
Tumwebaze, Patrick; Nsobya, Samuel L.; and Rosenthal, Philip J., "Lack of resistance of Plasmodium falciparum




Roland A. Cooper, Melissa D. Conrad, Quentin D. Watson, Stephanie J. Huezo, Harriet
Ninsiima, Patrick Tumwebaze, Samuel L. Nsobya, and Philip J. Rosenthal
This conference proceeding is available at Dominican Scholar: https://scholar.dominican.edu/all-faculty/89
Lack	  of	  resistance	  of	  Plasmodium	  falciparum	  to	  dihydroartemisinin	  in	  	  
Uganda	  based	  on	  parasitological	  and	  molecular	  assays	  
Roland	  A.	  Cooper,1	  Melissa	  D.	  Conrad,2	  QuenBn	  D.	  Watson,3	  Stephanie	  J.	  Huezo,1	  Harriet	  Ninsiima,4	  Patrick	  Tumwebaze,4	  Samuel	  L.	  Nsobya,4	  and	  Philip	  J.	  Rosenthal2	  
	  
Department	  of	  Natural	  Sciences	  and	  MathemaBcs,	  Dominican	  University	  of	  California,	  San	  Rafael,	  CA,	  USA;	  	  2Department	  of	  Medicine,	  University	  of	  California,	  San	  Francisco,	  USA;	  	  3Department	  of	  
IntegraBve	  Biology,	  University	  of	  California,	  Berkeley,	  USA;	  	  4InfecBous	  Diseases	  Research	  CollaboraBon,	  Kampala,	  Uganda	  
Introduction Results 
Methods 
References	  	  Acknowledgements	  	  
807	  
•  Artemisinin-­‐based	  combina0on	  therapy	  is	  now	  standard	  treatment	  
for	  falciparum	  malaria.	  However,	  this	  regimen	  is	  threatened	  by	  
resistance	  to	  artemisinins,	  manifest	  as	  delayed	  clearance	  of	  
parasitemia	  a=er	  therapy,	  in	  southeast	  Asia1.	  
•  Artemisinin	  resistance	  in	  southeast	  Asia	  is	  associated	  with	  increased	  
parasitemias	  in	  culture,	  compared	  to	  those	  in	  sensi0ve	  parasites,	  72	  
hours	  a=er	  a	  6	  hour	  pulse	  with	  700	  nM	  dihydroartemisinin	  (DHA),	  
and	  with	  propeller	  domain	  polymorphisms	  in	  the	  Plasmodium	  
falciparum	  kelch	  (K13;	  PF3D7_1343700)	  gene1,2.	  
•  Given	  that	  artemether/lumefantrine	  has	  been	  adopted	  as	  standard	  
therapy	  for	  malaria	  within	  the	  last	  decade	  in	  Uganda,	  we	  
characterized	  artemisinin	  sensiBvity	  in	  fresh	  P.	  falciparum	  isolates	  
from	  Kampala	  using	  ex	  vivo	  ring-­‐stage	  survival	  and	  IC50	  assays.	  We	  
also	  assessed	  the	  K13	  gene	  for	  polymorphisms.	  	  
	  
53	  fresh	  P.	  falciparum	  isolates	  were	  collected	  from	  pa0ents	  diagnosed	  
with	  malaria	  from	  May-­‐August	  2014,	  at	  Mulago	  Hospital,	  Kampala.	  	  	  
	  
Parasite	  IC50s	  to	  DHA	  were	  determined	  by	  a	  standard	  72	  h	  ex	  vivo	  
microplate	  assay	  using	  HRP2	  detec0on3.	  	  
	  
Parasite	  suscep0bility	  to	  DHA	  was	  assessed	  in	  the	  ex	  vivo	  ring-­‐stage	  
survival	  assay	  as	  described2.	  Survival	  rates	  were	  expressed	  as	  the	  
propor0on	  of	  parasites	  in	  the	  6	  h,	  700	  nM	  DHA-­‐pulsed	  cultures	  rela0ve	  to	  
DMSO	  controls,	  at	  the	  end	  of	  the	  72	  hour	  assay.	  Twelve	  cultures	  exposed	  
to	  DHA	  were	  allowed	  to	  grow	  for	  30	  d	  to	  test	  for	  recrudescence.	  
	  
K13	  propeller-­‐encoding	  domains	  (codons	  440-­‐726)	  were	  dideoxy	  
sequenced.	  Polymorphisms	  in	  pfcrt	  and	  pfmdr1	  were	  assessed	  with	  
mul0plex	  ligase	  detec0on	  reac0on-­‐ﬂuorescent	  microsphere	  assays	  as	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Fig.	  2.	  Ring-­‐stage	  survival	  assay.	  
Fig.	  1.	  Study	  site	  -­‐	  Kampala,	  UG.	  
Summary and Conclusions 
Fig.	  3.	  Prevalences	  of	  wild-­‐type,	  mixed,	  and	  
mutant	  sequences	  at	  the	  indicated	  
posiBons	  for	  all	  53	  isolates.	  
Fig.	  5.	  Two	  kelch	  13	  (K13)	  polymorphisms	  were	  detected	  from	  our	  samples.	  Numbered	  boxes	  indicate	  the	  
six	  blades	  comprising	  the	  propeller	  domain	  of	  the	  kelch	  13	  protein.	  
P.	  falciparum	  sequences	   BTB-­‐POZ	   1	   2	   3	   4	   5	   6	  
A578S	  S522C	  
NH2	  -­‐	  	  	   	  -­‐	  COOH	  	  
•  Ring-­‐stage	  survival	  was	  0%	  in	  40/43	  cultures	  
•  Ring-­‐stage	  survival	  ranged	  0.7	  -­‐	  1.9%	  in	  3/43	  cultures	  
•  No	  associaBon	  with	  survival	  and	  SNPs	  in	  K13,	  pfcrt	  or	  pfmdr1	  
•  Parasites	  reemerged	  from	  10/12	  long-­‐term	  cultures	  aaer	  DHA	  pulse	  
Fig.	  4.	  Ex	  vivo	  IC50	  values	  for	  DHA	  from	  15	  isolates.	  The	  
geometric	  mean	  IC50	  value	  was	  1.6	  nM.	  
Parasite	  isolate	  collec0on,	  ﬁlter	  papers	  
(N=53)	  
ex	  vivo	  IC50	  assays	  
(N	  =	  15)	  
ex	  vivo	  ring-­‐stage	  survival	  assays	  
(N	  =	  43)	  
gDNA	  from	  ﬁlter	  papers	  
for	  K13,	  pfcrt	  and	  pfmdr1	  
genotyping	  
	  Long	  term	  cultures	  to	  test	  for	  
recrudescence	  	  (N	  =	  12)	  
K13	  muta0ons	  were	  found	  in	  2/53	  parasite	  isolates	  from	  Kampala,	  but	  were	  not	  muta0ons	  
associated	  with	  resistance	  in	  SE	  Asia.	  
	  
RSA	  and	  IC50	  data	  showed	  that	  parasites	  remain	  highly	  sensi0ve	  to	  DHA	  in	  vitro.	  
	  
The	  results	  of	  this	  study,	  as	  well	  as	  ﬁndings	  from	  other	  studies5,	  suggest	  that	  artemisinin	  resistance	  
is	  not	  yet	  a	  problem	  in	  Uganda.	  The	  polymorphic	  nature	  of	  K13	  in	  Africa6	  and	  altered	  ACT	  partner	  
drug	  sensi0vity	  in	  Uganda4	  indicate	  the	  con0nued	  need	  for	  surveillance	  of	  ACT	  eﬃcacy	  in	  the	  
region.	  
	  
We	  thank	  Jenny	  Legac,	  Michelle	  Verghese,	  and	  Hadijah	  Nalubega	  for	  technical	  assistance.	  This	  work	  was	  
supported	  by	  NIH	  grants	  AI1R01AI075045	  and	  U19AI089674,	  Training	  in	  Malaria	  Research	  in	  Uganda	  
(D43TW007375)	  and	  University	  of	  California,	  Berkeley	  Minority	  Health	  &	  Health	  Dispari0es	  
Interna0onal	  Research	  Training	  (T37MD003407).	  
	  
1Ashley	  et	  al.	  (2014)	  N	  Engl	  J	  Med	  371:411-­‐423.	  2Witkowski	  et	  al.	  (2013)	  Infect	  Dis	  13:1043-­‐1049.	  
3Noedl	  et	  al.	  (2005)	  An0microb	  Agents	  Chemother	  49:3575–3577.	  4Conrad	  et	  al.	  (2014)	  J	  Infect	  Dis	  
210:344-­‐353.	  5Conrad	  et	  al.	  (2014)	  PLoS	  One	  9:e105690.	  6Fairhurst	  (2105)	  Curr	  Opin	  Infect	  Dis	  
28:417–425.	  
	  
